AMOXICILLIN ADDED TO OMEPRAZOLE PREVENTS RELAPSE IN THE TREATMENT OF DUODENAL-ULCER PATIENTS

被引：134

作者：

UNGE, P

GAD, A

ERIKSSON, K

BERGMAN, B

CARLING, L

EKSTROM, P

GLISE, H

GNARPE, H

JUNGHARD, O

LINDHOLMER, C

SANDZEN, B

STRANDBERG, L

STUBBEROD, A

WEYWADT, L

机构：

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 1993年 / 5卷 / 05期

关键词：

DUODENAL ULCER; HELICOBACTER-PYLORI ERADICATION; ULCER RELAPSE; OMEPRAZOLE AMOXICILLIN;

D O I：

10.1097/00042737-199305000-00005

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objective: To evaluate two different therapies, omeprazole/amoxicillin versus omeprazole alone, in the treatment of duodenal ulcer patients with respect to eradication of Helicobacter pylori and time in remission during a 6-month follow-up after cessation of therapy. Design: Double-blind, randomized, parallel groups. Setting. Outpatient referrals in nine Swedish centres. Patients: This study included 248 patients with active duodenal ulcer. Main outcome measures: Endoscopic and symptomatic evaluation of time in remission. Culture, histology and serology for determination of H. pylori status. Results: Eradication of H. pylori was 54 compared with 4% and the proportion of patients in remission at 6 months was 70 compared with 36% in the omeprazole/amoxicillin treated group versus the group treated with omeprazole alone. Of the patients who became H. pylori-negative, 84% were in remission throughout the study. Conclusion: H. pylori is an almost obligate prerequisite for duodenal ulcer disease. Amoxicillin added to omeprazole nearly doubled the proportion of patients in remission at 6 months follow-up. The eradication rate of H. pylori in patients with excellent compliance was 74%.

引用

页码：325 / 331

页数：7

共 13 条

[1] Tytgat G.N.J., Graham D.Y., Lee A., Marshall B.J., Dixon M.F., Axon A.T.R., Working party report to the World Congress of Gastroenterology, Sydney 1990, J Gastroenterol Hepatol, 6, pp. 103-140, (1991)
[2] Rauws E.A.J., Tytgat G.N.J., Cure of duodenal ulcer associated with eradication of, Helicobacter Pylori. Lancet, 335, pp. 1233-1235, (1990)
[3] Marshall B.J., Goodwin C.S., Warren J.R., Murray R., Buncow E.D., Blackbourn S.J., Et al., Prospective and double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori, Lancet, 2, pp. 1437-1442, (1988)
[4] Coghlan J., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Et al., Campylobacter pylori, Lancet, 2, pp. 1109-1111, (1987)
[5] Hkschl A., Stanek G., Potzi R., Rotter M., Wende L., Sensitivity of Campylobacter pylortdis to antimicrobial chemothera-peutics and drugs used for therapy of peptic ulcers [in German], Antimicrob Antineopl Cbemter, 4, pp. 45-49, (1986)
[6] Suerbaum S., Leying H., Klemm K., Opferkuch W., Antibacterial activity of pantoprazole and omeprazole against, Helicobacter Pylori. Eur J Din Microbiol Infect, 10, pp. 92-93, (1991)
[7] Stolte M., Bethke B., Elimination of Helicobacter pylori under treatment with omeprazole, Z Gastroenterol, 28, pp. 271-274, (1990)
[8] Unge P., Gad A., Gnarpe H., Olsson J., Et al., Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? a pilot study, Scarta J Gastroenterol, 24, pp. 49-54, (1989)
[9] Lamouuatte H., Megraud F., De Mascarel A., Barberis C., Bernard P.H., Cayla R., Does omeprazole improve amoxycillin therapy directed towards Campylobacter pylori-associated chronic gastritis [abstract], Klin Wocben-Scbr, 67, (1989)
[10] Goodwin C.S., Buncow E.D., Warren J.R., Waters T.E., Sanderson C.R., Easton L., Easton L Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa, J Clin Pathol, 38, pp. 1127-1131, (1985)

← 1 2 →